Clinical Trial Record

Return to Clinical Trials

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery


1999-10


2002-10


2002-10


N/A

Study Overview

Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery

RATIONALE: Palliative therapy with octreotide may help patients who have bowel obstruction that cannot be removed by surgery to live longer and more comfortably. PURPOSE: Phase II trial to study the effectiveness of octreotide as palliative therapy in treating patients who have cancer-related bowel obstruction that cannot be removed by surgery.

OBJECTIVES: * Determine the effectiveness of octreotide in the palliation of bowel obstruction secondary to cancer. * Characterize the dose and tolerability of octreotide in this patient population. OUTLINE: Patients receive octreotide subcutaneously or IV over 24 hours on days 2-5. Patients who respond well to study may continue octreotide for palliative effects. PROJECTED ACCRUAL: A total of 9-25 patients will be accrued for this study over 9 months.

  • Colorectal Cancer
  • Constipation, Impaction, and Bowel Obstruction
  • Extrahepatic Bile Duct Cancer
  • Gastric Cancer
  • Gastrointestinal Stromal Tumor
  • Nausea and Vomiting
  • Ovarian Cancer
  • Pancreatic Cancer
  • Peritoneal Cavity Cancer
  • Small Intestine Cancer
  • DRUG: octreotide acetate
  • NU 97X1
  • NU-97X1
  • NCI-G00-1685

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates Results Reporting Dates Study Record Updates

2000-03-07  

N/A  

2012-05-31  

2003-05-08  

N/A  

2012-06-06  

2003-05-09  

N/A  

2012-05  

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

Primary Purpose:
Supportive Care


Allocation:
N/A


Interventional Model:
N/A


Masking:
N/A


Arms and Interventions

Participant Group/ArmIntervention/Treatment
Secondary Outcome MeasuresMeasure DescriptionTime Frame

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person’s general health condition or prior treatments.

Ages Eligible for Study:
ALL

Sexes Eligible for Study:
18 Years

Accepts Healthy Volunteers:

    DISEASE CHARACTERISTICS:

  • Inoperable bowel obstruction secondary to cancer OR
  • Metastatic or primary abdominal cancer
  • Patient presents with vomiting
  • Percutaneous gastrostomy tube allowed

  • PATIENT CHARACTERISTICS:
    Age:

  • Over 18

  • Performance status:

  • ECOG 0-4

  • Life expectancy:

  • Not specified

  • Hematopoietic:

  • Not specified

  • Hepatic:

  • Not specified

  • Renal:

  • Not specified

  • Other:

  • No documented hypersensitivity to octreotide
  • Not pregnant or nursing

  • PRIOR CONCURRENT THERAPY:
    Biologic therapy:

  • Not specified

  • Chemotherapy:

  • Prior chemotherapy allowed

  • Endocrine therapy:

  • Concurrent steroids allowed

  • Radiotherapy:

  • Prior radiotherapy allowed

  • Surgery:

  • Not specified

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

  • National Cancer Institute (NCI)

  • STUDY_CHAIR: J. Cameron Muir, MD, Robert H. Lurie Cancer Center

Publications

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

No publications available